Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow DWTX by emailGet an email when DWTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DWTX, unsubscribe in one click. Privacy
📣 What DWTX Says Is Next
this fall · ““Dogwood is off to a strong operational start to 2026 driven by significant pipeline progress for both Halneuron ® , with Phase 2b data anticipated this fall, and SP16, which received FDA clearance to progress into Phase 1b development this quarter , ” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics.”
Company press release, May 14, 2026 · SEC filing
the end of 2026 · “Submitting our end of Phase 2 summary, manufacturing plans and Phase 3 clinical development plans to FDA towards the end of 2026, assuming favorable outcomes in our ongoing Halneuron ® Phase 2b program.”
Company press release, Mar 26, 2026 · SEC filing
fourth quarter of 2026 · “The Company believes that the cash and cash equivalents on hand at December 31, 2025 together with the net proceeds received in January 2026 of $11.4 million after deducting placement agent fees and offering expenses payable by the Company, is expected to fund operations through the Halneuron® Phase 2b final data readout and into the fourth quarter of 2026.”
Company press release, Mar 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full DWTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DWTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.